We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.50 | 123.00 | 130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2012 16:30 | One is reminded of the so-called "Animal House Excuse": Warning, one use of profanity. | stevie blunder | |
26/7/2012 13:55 | It's hard to post when I feel such a complete idiot for investing in this company. I just hope they sell it and I can forget about them. They should all be fired. | 1400 | |
25/7/2012 12:05 | One has to wonder what type of agreement they signed with st jude: Brown added that St. Jude holds the license in perpetuity, but he declined to address whether it would have to strike any new agreement with any potential acquirer to continue to access the technology. He added that AorTech is the sole supplier of the Optim polymer material, but St. Jude could elect to manufacture it on its own although it would prove to be a complicated, time-consuming process. | abc125 | |
24/7/2012 09:39 | Interesting Trade this morning... Maybe something about to happen.. | gac141 | |
23/7/2012 10:36 | Hi 1Prophet What's rumbling over where you are? | 25october1969 | |
20/7/2012 15:45 | Bit of a rumble over here. What's going on? | 1prophet | |
19/7/2012 17:44 | Yes Des it is interesting to see a change to the end of the article. You would really think that a multi billion $ company would have people who knew the facts. This is not the first time this mistake has been made. As time marches on you could see how attractive Aortech could be to a competitor not just the products for themselves but also as a strategic advantage over say St Jude.. We must be worthy of multiple discussions hence the Stock Exchange announcement. | gac141 | |
19/7/2012 15:58 | Worth checking out the Medcity News article again as there is an update at the bottom. It would appear that St Jude have had to issue a retraction of their claim that the Optim IP is theirs. Not for the first time over the last few months either !! | deswalker | |
19/7/2012 14:46 | Interesting article. Sounds a bit like a first round of negotiations in public. While I have seen at first hand very large companies argue about amounts you would feel they wouldn't even notice in this case I think we have seen that the value of St Jude can be impacted in the order of billions $ on a rumour that one Durata lead caused a problem. The thought of them taking any risk with Optim is totally out of the question and while we might not get the great auction we hoped for surely they will pay £20m+ just to get this sorted and out of the papers. Can you imagine them putting out an announcement that says " we note the recent acquisition of AOR by Medtronic and confirm that we look forward to continuing our supply agreement with Optim's new owner Medtronic". I can't so i still believe the plan is in tact here although the share price fall is scary and annoying. | harrogate | |
19/7/2012 13:53 | Des, I sincerely hope you are right but I have always been frustrated by the lack of disclosure by this company. So many unspecific deals etc., etc., Perhaps this latest article will attract more attention to Aortech. Of course, no news regarding polymer heart valve... | 1400 | |
19/7/2012 11:54 | Hi Des Totally agree with your post and hope the pressure is being applied by hungry American newshounds scenting blood or at least another damming appology from Dan Starks over missleading and innaccurate statements over IP ownership by certain St Jude spokesmen. I can only guess St Jude are running scared from concerned shareholders and by casting doubt on ownership of Elasteon feel they can pick us up on the cheap by putting others off.I feel they have missed the boat on that one and look forward to the next installment which could result in the desired competitive auction. Heres hoping regards Sp | spurious | |
19/7/2012 11:13 | Cheers for finding that Stevie. Not for the first time it seems that St Jude are spinning a yarn about the ownership of Optim and it's good to see our Chairman speaking out against this spin. St Jude have bought our silence for long enough. If I were a large institutional shareholder of St Jude stock I would not only want to understand the precise situation but I would also be asking why they appear to be playing so fast and loose with the legalities of Optim ownership. I would also be asking questions as to why the St Jude CEO isn't making this problem go away in a neat and tidy fashion for a very very modest sum of money. | deswalker | |
19/7/2012 09:07 | Medcity news piece, war of words between St Jude and Aortech: "I can categorically confirm that the intellectual property rights over the material that is known as Elast-Eon that St. Jude has re-branded as Optim is owned by AorTech International plc," Brown said in an interview from the U.K. Tuesday. "I have to say that I was really quite upset to read in your journal claims from St. Jude people that they had spent 10 years in developing Optim. It is our material. They have a license. It is not their material."" | stevie blunder | |
16/7/2012 18:42 | Of course, I'm hanging on for a take over at a much higher price. But, is there anything in the past that gives me any hope this will happen. No! And while I'm on about it who wins out on the Board between the founders and AIT a declared seller? Smells like a major conflict of interest to me. Should have sold on the announcement. | 1400 | |
16/7/2012 15:33 | seeing as it is 3 months till the cash has gone and its lights out, any bidder has time on his hands. St Judes could pick it up for a few mill? | the prophet | |
16/7/2012 15:27 | Doesnt look like the market is attaching any value to a bid coming in for AOR everyday now the share price drops on minimal vol and mms offering stock so easily as I type WINS are offering 15 000 at 200.75p Could this scenario occur? AOR goes into administration STJM pick up the IP from administrators for next to nothing directors and staff sign new contracts and become STJM employees | papillon88 | |
16/7/2012 15:13 | Imbecilic behavior from the management as usual. | 1400 | |
13/7/2012 12:15 | St Jude can't walk away because of Optim, Bluehone wants to liquidate. So who's in charge here? | 1400 | |
13/7/2012 10:08 | Well, the reality is the options will be worthless/unexercise | bearfoot | |
13/7/2012 09:54 | I agree with Vega- Pither has done nothing for AOR. If you can't make sales when you are in the Epicenter of the Medical device community, with one of the best products available.... well you fill in the blanks | gac141 | |
13/7/2012 09:10 | If the company is sold I'd rather not loose 6% of my upside from these levels. I wouldn't mind so much if it were going to some of the other board members, but not those two. | vega44 | |
13/7/2012 08:52 | Given the situation the deal will be done and we will be happy and they can have the options for me or it won't and they are worthless. They don't look that excessive compared to many BOD grants so I personally this is the least of mu worries at the moment about AOR | harrogate | |
13/7/2012 08:47 | I hope that Pither and Maguire will have the integrity to give up their options as a way of apologising to shareholders for all the value they have destroyed in recent years. Perhaps this needs to be put to the board? | vega44 | |
12/7/2012 13:53 | thanks des | papillon88 | |
12/7/2012 13:23 | Under the takeover rules anyone with over 1% is supposed to declare their holding. | deswalker |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions